{"url_path":"/sec/xoma/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/791908/0001193125-26-228031-index.html","accession_number":"0001193125-26-228031","cik":"0000791908","ticker":"XOMA","issuer_name":"XOMA Royalty Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/791908/0001193125-26-228031-index.html","primary_entity_key":"0000791908","primary_entity_name":"XOMA Royalty Corp"},"word_count":109,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit No.\n  \n\nDescription\n\n2.1\n  \n\n[Amendment No. 1 to the Agreement and Plan of Merger, dated as of May 16, 2026, by and among XOMA Royalty Corporation, XOMA Royalty Holdings Corporation, Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc.](d130820dex21.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nXOMA ROYALTY CORPORATION\n\nDate: May 18, 2026\n\n \n\nBy:\n\n \n\n/s/ Owen Hughes\n\n \n\n \nName:\n \n\nOwen Hughes\n\n \n\n \nTitle:\n \n\nChief Executive Officer"}